Expanding Treatment for CNS Conditions

We are committed to developing products that meaningfully improve the lives of patients.

Axsome is developing innovative treatments including AXS-05, AXS-07, AXS-12, and AXS‑14.

Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

learn about these CNS conditions & more

AXS-05 AXS-07

AXS-12 AXS-14

recent news

Auvelity™ is now approved!

Please see full Prescribing Information, including Boxed Warning, and the Medication Guide.

view website

Axsome Therapeutics Completes U.S. Acquisition of Sunosi®

Please see full Prescribing Information and Medication Guide.

view press release

Click here to read more

Click to here read more

See all News

Working at Axsome

Join our team! Take a look at available positions.

see opportunities

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

Turning patient needs into breakthrough discoveries.

Turning patient
needs into
breakthrough
discoveries.

We are committed to developing products that meaningfully improve the lives of patients.

recent news

Working at Axsome

We are committed to developing products that meaningfully improve the lives of patients.

recent news

Working at Axsome

your privacy is important to us

You are about to leave axsome.com

You are about to
leave axsome.com